MapLight Therapeutics, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
MapLight Therapeutics filed an 8-K on 2026-11-16 disclosing entry into a material definitive agreement under Item 1.01. The filing provides no concrete details regarding counterparties, dollar amounts, percentages, share counts, dates, or the nature of the agreement. Exhibits referenced in the filing index are not provided in the accessible text.
Why this rating
Material agreement disclosed but zero specifics provided. Cannot assess magnitude relative to $368M asset base without terms, counterparty, or value. Routine disclosure lacking substantive detail.
Extracted items
- 1.01 material agreement
- 9.01 exhibits
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.